EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention

Eun Ho Choo, Donggyu Moon, Ik Jun Choi, Sungmin Lim, Jungkuk Lee, Dongwoo Kang, Byung-Hee Hwang, Chan Joon Kim, Jong-Min Lee, Ki-Dong Yoo, Doo Soo Jeon, Kiyuk Chang

Cardiovascular Diabetology · 2024

DOI: 10.1186/s12933-024-02498-3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cardiovascular Diabetology, 2024. Verfasst von Eun Ho Choo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Rep…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Databases, Factual, Diabetes Mellitus, Dyslipidemias. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds High-intensity statin is recommended for patients undergoing percutaneous coronary intervention (PCI), and ezetimibe is recommended to be added in patients not achieving low-density lipoprotein cholesterol (LDL-C) targets. Moderate-intensity statin plus ezetimibe can reduce LDL-C levels similar to high-intensity statin. The aim of this study is to examine the long-term efficacy and safety of moderate-intensity statin plus ezetimibe as the first-line strategy compared to high-intensity statin in patients undergoing PCI.

Method

Data was obtained from the Health Insurance Review and Assessment Service database of South Korea. Patients who underwent PCI from 2012 to 2017 were included. The primary efficacy endpoint was major adverse cardiac cerebrovascular events (MACCEs), a composite of all-cause death, revascularization, or ischemic stroke. The safety endpoint was new-onset diabetes mellitus (DM).

Results

A total of 45,501 patients received high-intensity statin ( n = 38,340) or moderate-intensity statin plus ezetimibe ( n = 7,161). Among propensity-score-matched 7,161 pairs, MACCEs occurred in 1,460 patients with high-intensity statin and 1,406 patients with moderate-intensity statin plus ezetimibe (33.8% vs. 31.9%, hazard ratio 0.96, 95% confidence interval 0.89–1.03, P = 0.27) at a median follow-up of 2.7 years. DM was newly diagnosed in 398 patients with high-intensity statin and 342 patients with moderate-intensity statin plus ezetimibe (12.5% vs. 10.7%; hazard ratio 0.84, 95% confidence interval 0.73–0.97, P = 0.02).

Conclusion

In patients undergoing PCI, moderate-intensity statin plus ezetimibe demonstrated a similar risk of MACCEs but a lower risk of new-onset DM than high-intensity statin. Early combination treatment of moderate-intensity statin and ezetimibe may be a useful and safe lipid-lowering strategy after PCI. Graphical abstract Cumulative incidence according to the first-line lipid-lowering strategy in patients undergoing percutaneous coronary intervention. Abbreviation: MACCE, major adverse cardiac cerebrovascular events; PCI, percutaneous coronary intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseDatabases, FactualDiabetes MellitusDyslipidemiasEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsPercutaneous Coronary InterventionAgedFemaleHumansMaleMiddle AgedAnticholesteremic AgentsBiomarkersCholesterol, LDLDrug Therapy, CombinationRepublic of KoreaRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Coronary artery diseaseDyslipidemiaEzetimibePercutaneous coronary interventionStatin

Substanzen

Anticholesteremic AgentsBiomarkersCholesterol, LDLEzetimibeHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Cardiology, Department of Internal Medicine, St Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. mrfasthand@catholic.ac.kr.
  • Division of Cardiology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 56 Dongsu-ro, Bupyeong-dong, Bupyeong-gu, 21431, Incheon, Seoul, Republic of K…
  • Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. mdsungminlim@gmail.com.

Zitieren

APA

Choo, E. H., Moon, D., Choi, I. J., Lim, S., Lee, J., Kang, D., Hwang, B. H., Kim, C. J., Lee, J. M., Yoo, K. D., Jeon, D. S., & Chang, K. (2024). Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-024-02498-3

Vancouver

Choo EH, Moon D, Choi IJ, Lim S, Lee J, Kang D, et al. Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention. Cardiovascular Diabetology. 2024. doi:10.1186/s12933-024-02498-3

BibTeX
@article{Choo2024,
  author = {Choo, Eun Ho and Moon, Donggyu and Choi, Ik Jun and Lim, Sungmin and Lee, Jungkuk and Kang, Dongwoo and Hwang, Byung-Hee and Kim, Chan Joon and Lee, Jong-Min and Yoo, Ki-Dong and Jeon, Doo Soo and Chang, Kiyuk},
  title = {Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention},
  journal = {Cardiovascular Diabetology},
  year = {2024},
  doi = {10.1186/s12933-024-02498-3}
}
Kostenlos starten →